Glibenclamide Tablets IP 5 mg Manufacturer

Glibenclamide Tablets IP 5 mg Manufacturer in India – Healthy Life Pharma Pvt. Ltd.

Glibenclamide Tablets IP 5 mg Manufacturer product packaging

Glibenclamide Tablets IP 5 mg | Manufacturer

Product image for Glibenclamide Tablets IP 5 mg Manufacturer; contract manufacturing, oem & quality control.

Product Information

Generic NameGlibenclamide
ManufacturerHealthy Life Pharma Pvt. Ltd.
HSN Code30049099
PharmacopoeiaIP
Product TypeTablet
CategoryAntidiabetic drugs
SubcategoryAntidiabetic drugs
Active IngredientGlibenclamide
Strength5 mg
Dosage FormTablet
Pack Size10 x 10 Tablets / Box (Alu-Alu / Blister)
Route of AdministrationOral
Prescription RequiredYes
Therapeutic CategoryAntidiabetic drugs

Medicine Details & Safety

Short DescriptionHealthy Life Pharma invites contract and third-party manufacturing enquiries for Glibenclamide Tablets IP 5 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements.
Approved Uses / Indications1. Monotherapy as an adjunct to diet and exercise for glycemic control in type 2 diabetes mellitus. 2. Combination therapy with other oral antidiabetic agents or insulin when dual therapy is required.
Full Description

Healthy Life Pharma invites contract and third-party manufacturing enquiries for Glibenclamide Tablets IP 5 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements.

Product technical specifications

Generic nameGlibenclamide
CompositionGlibenclamide
Strength5 mg
CategoryAntidiabetic drugs
PharmacopoeiaIP
Dosage formTablet

Product technical specifications

Generic nameAcarbose
CompositionAcarbose
Strength25 mg
CategoryAntidiabetic Drugs
PharmacopoeiaUSP / IP
Dosage formTablet

Manufacturing capabilities and infrastructure

For Glibenclamide Tablets IP 5 mg, assess the approved formulation process, equipment suitability, batch scale and in-process controls for the Tablet presentation. Confirm environmental requirements and validated process before production.

Quality control and assurance

Request the approved finished-product specification for Glibenclamide Tablets IP 5 mg, including applicable identity, assay, uniformity and performance tests for the Tablet presentation. Confirm analytical methods, acceptance criteria and batch release documentation, including COA availability.

Primary and secondary packaging

The catalogue pack for Glibenclamide Tablets IP 5 mg is 10 x 10 Tablets / Box (Alu-Alu / Blister). Confirm primary packaging compatibility, stability evidence, artwork, batch coding and leaflet requirements against the approved specification.

Contract manufacturing and private label

Submit the target market, strength, pharmacopoeial specification, forecast volume and brand artwork. Agree feasibility, batch size, quality agreement, production schedule and release criteria before execution.
Dosage InstructionsAdminister orally with meals or immediately before food intake as directed by the physician. Recommended dosage should be individualized based on glycemic response and HbA1c targets. Maintain regular blood glucose self-monitoring during initiation and titration.
Side EffectsCommon: Mild gastrointestinal discomfort, nausea, flatulence, abdominal fullness, diarrhea. Uncommon: Hypoglycemia (when combined with other antidiabetic agents), transient metallic taste, mild headache. Rare: Skin rash, urticaria, elevated hepatic transaminases.
Warnings and PrecautionsHypoglycemia Risk: Concomitant use with sulfonylureas or insulin secretagogues heightens hypoglycemic risk; ensure immediate access to fast-acting carbohydrates. Renal & Hepatic Monitoring: Periodically assess serum creatinine, eGFR, and liver function tests during long-term therapy.
Contraindications1. Known hypersensitivity to Glibenclamide or formulation excipients.
2. Diabetic ketoacidosis, hyperosmolar hyperglycemic state, or diabetic coma.
3. Severe renal impairment (eGFR < 30 mL/min) or advanced hepatic insufficiency.
4. Acute metabolic acidosis.
Drug Interactions1. Sulfonylureas, Meglitinides & Insulin: Enhanced hypoglycemic effect requiring dose adjustments.
2. Corticosteroids, Thiazides & Sympathomimetics: May attenuate glycemic control, requiring upward titration.
3. Alcohol: May potentiate hypoglycemia or risk of metabolic acidosis.

Frequently Asked Questions

QuestionAnswer
Can I request third-party manufacturing for Glibenclamide Tablets IP 5 mg?Submit your brand, quantity and packaging requirements for manufacturing feasibility review.
Which pharmacopoeial standard applies for Glibenclamide Tablets IP 5 mg?The source specification is IP; confirm the required standard before contracting.
What quality tests are applicable for Glibenclamide Tablets IP 5 mg?Request the approved finished-product specification and batch testing plan.
Can packaging be customized for Glibenclamide Tablets IP 5 mg?Submit artwork and pack requirements for technical and regulatory review.
How do I request a manufacturing quotation for Glibenclamide Tablets IP 5 mg?Provide forecast volume, target market, strength and packaging requirements.

Product Hashtags

#Glibenclamide#Manufacturer#PharmaB2B

Related Products

Related Posts